Cipla Of India Markets Generic of Bayer's Kidney Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
India's Cipla has launched at home a generic version of Nexavar (sorafenib) marketed by Germany's Bayer to treat kidney cancer
You may also be interested in...
Sharing "Schering" Link Gets Bayer And Cadila To Talk Joint Venture; Deal Spanning Market To Manufacturing Likely In Final Stages
MUMBAI - Germany-headquartered agrichemicals-to-healthcare behemoth Bayer is talking to India's Cadila Healthcare to form an equal stake joint venture that will revolve around selling its own branded and generic products as well as contracting out a significant part of its manufacturing requirements
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.